Eshita Varma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eshita Varma has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Hofmann
Department of Internal Medicine III (Cardiology, Angiology, and Pneumology [C.H., A.S., O.M.S., J.F., F. Sicklinger, F.S.Y., I.S.M., E.M., C. Sandmann, L.J., V.K.-S., C. Stroh, Z.L., D.F., E.B., H.A.K., N.F., F.L., M.V.]), Heidelberg University Hospital, Germany
2 shared publications Lonny Jürgensen
Department of Cardiology, Angiology and Pneumology University Hospital Heidelberg Heidelberg Germany
2 shared publications- Mirko Völkers
Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
2 shared publications Verena Kamuf-Schenk
Department of Cardiology, Angiology and Pneumology University Hospital Heidelberg Heidelberg Germany
2 shared publications- Vivien Kmietczyk
Department of Internal Medicine III (Cardiology, Angiology, and Pneumology), Heidelberg University Hospital
2 shared publications A. Gorska
Department of Internal Medicine III (Cardiology, Angiology, and Pneumology), Heidelberg University Hospital
1 shared publication
Latest Publications
- Open Access
Ythdf2 regulates cardiac remodeling through its m 6 A-mRNA target transcripts
M 6 A mRNA methylation controls cardiomyocyte function and increased overall m 6 A levels are a stereotyping finding in heart failure independent of the underlying etiology. However, it is largely unknown how the information is read by m 6 A reader proteins in heart failure. Here we show that the m 6 A reader protein Ythdf2 controls cardiac function and identified a novel mechanism how reader proteins control gene expression and cardiac function. Deletion of Ythdf2 in cardiomyocytes in vivo leads to cardiac hypertrophy, reduced heart function, and increased fibrosis during pressure overload as well as during aging. Similarly, in vitro the knockdown of Ythdf2 results in cardiomyocyte growth and remodeling. Mechanistically, we identified the eucaryotic elongation factor 2 as a major target of Ythdf2 using cell type specific Ribo-seq data. Our study expands our understanding on the regulatory functions of m 6 A methylation in cardiomyocytes and how cardiac function is controlled by the m 6 A reader protein Ythdf2.
Open AccessYthdf2 regulates cardiac remodeling through its m 6 A-mRNA target transcripts
M 6 A mRNA methylation controls cardiomyocyte function and increased overall m 6 A levels are a stereotyping finding in heart failure independent of the underlying etiology. However, it is largely unknown how the information is read by m 6 A reader proteins in heart failure. Here we show that the m 6 A reader protein Ythdf2 controls cardiac function and identified a novel mechanism how reader proteins control gene expression and cardiac function. Deletion of Ythdf2 in cardiomyocytes in vivo leads to cardiac hypertrophy, reduced heart function, and increased fibrosis during pressure overload as well as during aging. Similarly, in vitro the knockdown of Ythdf2 results in cardiomyocyte growth and remodeling. Mechanistically, we identified the eucaryotic elongation factor 2 as a major target of Ythdf2 using cell type specific Ribo-seq data. Our study expands our understanding on the regulatory functions of m 6 A methylation in cardiomyocytes and how cardiac function is controlled by the m 6 A reader protein Ythdf2.
- Open Access
- 4 October 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (12) , e52170
Muscle-specific Cand2 is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 4 October 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (12) , e52170
Open AccessMuscle-specific Cand2 is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Identification of Dynamic RNA-Binding Proteins Uncovers a Cpeb4-Controlled Regulatory Cascade During Pathological Cell Growth of Cardiomyocytes
RNA binding proteins (RBPs) have the potential to affect most post-transcriptional steps in gene expression. RBPs control critical elements of cellular function, but their specific role in cardiomyocytes is largely unknown. Here we defined RBPs in healthy and diseased primary cardiomyocytes at a system-wide level by RNA Interactome Capture. This identified 67 novel cardiomyocyte specific RBPs including several contractile proteins. Furthermore, we identified Cytoplasmic polyadenylation element binding protein 4 (Cpeb4) as a dynamic mRBP in diseased cardiomyocytes, regulating cardiac growth both in vitro and in vivo. To study Cpeb4 in cardiomyocytes, we identified mRNAs bound to and regulated by Cpeb4. Cpeb4 regulates cardiac remodeling by differential expression of transcription factors. Among Cpeb4 target mRNAs, two Zinc finger transcription factors (Zeb1 and Zbtb20) were identified. We show that Cpeb4 regulates the translation of these mRNAs and that Cpeb4 depletion increases their expression. Thus, Cpeb4 emerges as critical regulator of cardiomyocyte function by differential binding of specific mRNAs in response to pathological growth stimulation.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessIdentification of Dynamic RNA-Binding Proteins Uncovers a Cpeb4-Controlled Regulatory Cascade During Pathological Cell Growth of Cardiomyocytes
RNA binding proteins (RBPs) have the potential to affect most post-transcriptional steps in gene expression. RBPs control critical elements of cellular function, but their specific role in cardiomyocytes is largely unknown. Here we defined RBPs in healthy and diseased primary cardiomyocytes at a system-wide level by RNA Interactome Capture. This identified 67 novel cardiomyocyte specific RBPs including several contractile proteins. Furthermore, we identified Cytoplasmic polyadenylation element binding protein 4 (Cpeb4) as a dynamic mRBP in diseased cardiomyocytes, regulating cardiac growth both in vitro and in vivo. To study Cpeb4 in cardiomyocytes, we identified mRNAs bound to and regulated by Cpeb4. Cpeb4 regulates cardiac remodeling by differential expression of transcription factors. Among Cpeb4 target mRNAs, two Zinc finger transcription factors (Zeb1 and Zbtb20) were identified. We show that Cpeb4 regulates the translation of these mRNAs and that Cpeb4 depletion increases their expression. Thus, Cpeb4 emerges as critical regulator of cardiomyocyte function by differential binding of specific mRNAs in response to pathological growth stimulation.